ABUS vs PTC · P/E 5.4, rev $6.2M vs P/E 48, rev $2.74B
Arbutus Biopharma Corp (ABUS) versus PTC Inc (PTC) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
PTC Inc (PTC) is a software - application company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported PTC revenue for 2025-09-30 was $2.74B. Net income was $734.0M. Revenue was up 19.2% from 2024-09-30 to 2025-09-30. PTC currently screens at market cap $21.11B and trailing P/E 48.3.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. PTC currently screens at market cap $21.11B and trailing P/E 48.3.
Not investment advice. Open the ABUS and PTC stock pages for the full models.
Not investment advice.